Genmab A/S
GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$50.60−0.75 (-1.46%)
Close on Nov 20, 2026
Genmab A/S Phase 2 Sponsored Interventional Studies: 68 in Q3 2026, up 7.9% from a year earlier. That is the highest of the 43 quarters on record here.
Latest, Q3 2026
68
Period ended Sep 30, 2026
Change on a year earlier
+7.9%
63 in Q3 2025
History
43 quarters
Since Q1 2016
Sources
1
NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies
Where the Q3 2026 figure comes from
Source: NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Genmab A/S Phase 2 Sponsored Interventional Studies, quarterly Q1 2016–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/ctgov-phase2-studies
See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.
See a number that looks wrong?